Subtype
Benign Central Nervous System Neoplasm
CI-CAN-00000486Explore in graph →
Non-malignant19 active trials
- NCIt
- C188049
Loading cancer entity…
Subtype
CI-CAN-00000486Explore in graph →
Clinical trials
76 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06357377 | A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors | recruiting | Phase 1 | 12 | Neonc Technologies, Inc.INDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05919264 | FOG-001 in Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 619 | Parabilis Medicines, Inc.INDUSTRY | 2 | Aug 17, 2026 | clinicaltrials |
| Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma |
| recruiting |
| Phase 1 / Phase 2 |
| 57 |
| Nanfang Hospital, Southern Medical UniversityOTHER |
| 1 |
| Nov 18, 2025 |
| clinicaltrials |
Data updated 15 days agoSource updated Sep 15, 2026source: clinicaltrials